The effects of delayed gastric emptying may further compound the risk factors harbored by the obese, diabetic patient: Gastroparesis secondary to diabetes-related autonomic dysfunction Bowel dysmotility from opioids (chronic pain) and prolonged bed-rest Altered oesophageal-gastric anatomy from bariatric surgery Gastric insufflation from overzealous bag-valve ventilation with high PEEP and difficult airway Reduced efficacy of routine antiemetic regime Nausea and vomiting are reported by approximately 50% of patients using GLP-1 agonists, as direct results of reduced gastric motility and activation of central satiety centers
This outcome highlights the complexity of the microbial ecosystem in the gut, wherein various microorganisms may possess the capacity to modulate GLP-1 levels
Delgado will explain the risks and complications of dermatologic surgery and plastic surgery involved in your care
Perioperative considerations With their superiority in glycaemic control, low incidence of fasting hypoglycaemia, roles in weight management, and established evidence for their cardiovascular benefits, GLP-1 agonists present as highly attractive agents in improving patient outcomes in the perioperative setting, with growing interest for these agents to be continued without perioperative interruption
These generally improve as the body adjusts or when the dose is increased gradually
